



zymeworks

Zymeworks to Present at 37th Annual Canaccord Genuity Growth Conference

August 4, 2017

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. ("Zymeworks") (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced it will present at the 2017 Canaccord Genuity Growth Conference taking place August 9-10, 2017 in Boston, Massachusetts.

Presentation Details:

Event: 37th Annual Canaccord Genuity Growth Conference
Date/Time: August 10, 2017 at 1:30 p.m. EDT
Location: Boston, MA

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks' suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks' lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks' wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20170804005653/en/): <http://www.businesswire.com/news/home/20170804005653/en/>

Investor Inquiries:
David Matousek, (604) 678-1388
Senior Manager, Investor Relations & Corporate Communications
[\[email protected\]](#)

Source: Zymeworks Inc.